Detalhe da pesquisa
1.
Exagamglogene Autotemcel for Severe Sickle Cell Disease.
N Engl J Med
; 390(18): 1649-1662, 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38661449
2.
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and ß-Thalassemia.
N Engl J Med
; 384(3): 252-260, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33283989
3.
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Blood
; 139(19): 2931-2941, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007321
4.
Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors.
Haematologica
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38721749
5.
High dose total marrow irradiation (TMI) does not increase long-term toxicity of myeloablative fludarabine/busulfan (FluBu4) conditioning regimen in allogeneic hematopoietic stem cell transplantation (HSCT).
Eur J Haematol
; 113(1): 110-116, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38566462
6.
"Window of Opportunity" in Ocular Graft-Versus-Host Disease Treatment: Results of a Longitudinal Study and Case Reports.
Eye Contact Lens
; 50(5): 222-232, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38477832
7.
Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease.
Blood
; 136(5): 623-626, 2020 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32518950
8.
A comparison of four leukapheresis methods to harvest an optimal dose of CD34+ cells: A single center experience.
Eur J Haematol
; 109(6): 711-718, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36030395
9.
Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres.
Br J Haematol
; 192(4): 761-768, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33534948
10.
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Blood
; 134(18): 1498-1509, 2019 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31515250
11.
Chromatin-Modifying Agent-Expanded Human Cord Blood Cells Display Reduced Allostimulatory Capacity.
J Immunol
; 202(8): 2493-2501, 2019 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30842275
12.
Race/ethnicity and underlying disease influences hematopoietic stem/progenitor cell mobilization response: A single center experience.
J Clin Apher
; 36(4): 634-644, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34046928
13.
Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan.
J Oncol Pharm Pract
; 27(3): 579-587, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32493164
14.
PARP Inhibition Synergizes with Melphalan but Does not Reverse Resistance Completely.
Biol Blood Marrow Transplant
; 26(7): 1273-1279, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32194286
15.
Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant.
Br J Clin Pharmacol
; 86(11): 2165-2173, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32285957
16.
Polypharmacy and potentially inappropriate medication use is highly prevalent in multiple myeloma patients and is improved by a collaborative physician-pharmacist clinic.
J Oncol Pharm Pract
; 26(3): 536-542, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31189419
17.
Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
Biol Blood Marrow Transplant
; 25(5): 855-860, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30615982
18.
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.
Biol Blood Marrow Transplant
; 25(6): 1142-1151, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30625392
19.
Non-myeloablative allogeneic HSCT in adult patients with sickle cell disease: Multiple take-home points from the Saudi Arabia experience.
Am J Hematol
; 99(6): 1021-1022, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38606977
20.
A novel drug interaction between busulfan and blinatumomab.
J Oncol Pharm Pract
; 25(1): 226-228, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28857712